340B: Multiple Perspectives

An ICAN^® International Cancer Advocacy Network Webinar—Hosted and Recorded July 16, 2025

Brief Overview:

A one-hour webinar (including questions) to bring participants up to speed on the latest developments regarding the U.S. 340B Drug Pricing Program at the federal, state, and judicial levels, and set the stage for the fall federal and state legislative sessions.

See the video of the Webinar which is posted on the ICAN YouTube Channel.

 

Moderator:

• Dr. Robert Popovian, Pharm D., MS, Founder, Conquest Advisers; Visiting Fellow, Pioneer Institute
• Dr. Popovian recommends Pioneer Institute's 340B Resources: Private-Sector-Profiteering-Through-the-Expansion-of-a-Federal-Program-Intended-to-Help-the-Poor—Pioneer Institute, Public Policy Research

Participants:

• Erin Arnold, MD, Coalition of State Rheumatology Organizations (CSRO) Board Member
• Slides used in Dr. Arnold's presentation
• Lisa Bercu, JD, Senior Director of Health Policy, National Consumers League
• Slides used in Lisa Bercu's presentation
• Lisa Bercu, JD recommends: 340B by State, What Adults Across States Think About the 340B Drug Pricing Program—National Consumer League
• Nicolas Ferreyros, Managing Director, Community Oncology Alliance (COA)
• Nic Ferreyros recommends these links:
• How 340B Disproportionate Share Hospitals (DSH) are failing to reinvest in patient care—Magnolia Market Access
• Regarding the role of Pharmacy Benefit Managers in the 340B Program: check out Chapter 1 of our (COA) research: COA PRESCRIPTION FOR HEALTH CARE REFORM: A POLICY BLUEPRINT FOR CONGRESS—Community Oncology Alliance
• This COA study also highlights 340B markups (5-11x) and profits on cancer drugs: Examining 340B Hospital Price Transparency, Drug Profits, and Incentives—Community Oncology Alliance
• Kathy Oubre, MS, CEO, Pontchartrain Cancer Center
• Kalvin Pugh, State 340B Policy Director, Community Access National Network (CANN)
• Slides used in Kalvin Pugh's presentation

Host:

• Ashraf Abdelghany, MD, Director of Research, ICAN, International Cancer Advocacy Network



Background on 340B

The 340B Drug Pricing Program (U.S. Health Resources and Services Administration Drug Pricing Program—Sec. 340B Public Health Services Act, Limitation of Prices of Drugs Purchased by Covered Entities) was originally designed for low-income and uninsured patients to have access to discounted prescription drugs. Unfortunately, the program has been abused and is now the second largest prescription drug program in the country (next to Medicare), and it is not adequately serving the low-income and uninsured patients it was designed to help. 

Purpose of the Webinar:

ICAN hosted a panel of experts to participate in a webinar to discuss the program. ICAN's webinar, 340B: Multiple Perspectives offers a variety of different viewpoints on what is wrong with the program and how it can be reformed.

ICAN's webinar, 340B: Multiple Perspectives was designed to update the audience—patients, physicians, pharmacists, legislative staff, healthcare administrators, patient advocates, and other interested parties—on 340B and where reform efforts may be going in the states, the federal government, and the courts.

Anyone concerned about the rising costs of prescription drugs should be interested in this discussion.

ICAN, International Cancer Advocacy Network

This webinar was organized by ICAN, International Cancer Advocacy Network. ICAN aids Stage IV cancer patients throughout the United States and around the world.  ICAN connects patients to clinical trials, second opinions, molecular profiling, and compassionate use.  Founded in 1996, and based in Phoenix, ICAN is in its 29th year and has provided patient navigation and other services to more than 19,500 patients.